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Cell motility is an important cellular function closely related to the processes of tumour progression and metastasis. Several members
of transmembrane 4 superfamily (TM4SF) have been reported to be associated with cell motility and metastatic potential of solid
tumour. The aim of this study is to clarify the clinical significance of the member of TM4SF (MRP-1/CD9, KAI1/CD82 and CD151) in
human colon cancer. We studied 146 colon cancer patients who underwent curative surgery and studied the expression of MRP-1/
CD9, KAI1/CD82 and CD151 using reverse transcriptase – polymerase chain reaction and immunohistochemistry. We found that 64
patients (43.8%) had MRP-1/CD9-positive tumours and that the overall survival rate of patients with MRP-1/CD9-positive tumours
was much higher than that of patients with MRP-1/CD9-negative tumours (89.8 vs 50.8%, Po0.001). In contrast, 63 patients (43.2%)
had KAI1/CD82-positive tumours and the overall survival rate of patients with KAI1/CD82-positive tumours was also higher than that
of patients with KAI1/CD82-negative tumours (84.8 vs 54.9%, P¼0.002). On the other hand, positive CD151 expression had a bad
effect on the overall survival rate of patients with colon cancer (61.2 vs 74.9%, P¼0.022). In a multivariate analysis, MRP-1/CD9 status
was a good indicator of the overall survival (P¼0.007). We have shown that the reduction of MRP-1/CD9 and KAI1/CD82
expression, and the increasing CD151 expression are indicators for a poor prognosis in patients with colon cancer. This is a first
report describing about the relation between CD151 and colon cancer.
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Cell motility plays an important key function related to the process
of tumour progression and metastasis (Miyake and Hakomori,
1991). It is partially dependent on adhesion molecules and
proteases (Hashida et al, 2001, 2002a). Previously, we reported
that the motility-related protein-1 (MRP-1) is an antigen
recognised by monoclonal antibody (MAb) M31-15 which inhibits
cell motility and the MRP-1 sequence coincides with the cluster of
differentiation antigen 9 (CD9) (Miyake et al, 1991). In our
previous reports, we showed MRP-1/CD9-overexpressing tumour
cells negative cell motility and metastatic potential (Ikeyama et al,
1993). Therefore, MRP-1/CD9 regulates cell motility and is a
receptor for negative signal ligands. In addition, negative MRP-1/
CD9 expression was associated with a poor prognosis in breast
cancer (Miyake et al, 1996), lung cancer (Higashiyama et al, 1995)
and pancreatic cancer (Sho et al, 1998). These data also suggest
that MRP-1/CD9 expression might be associated with metastatic
ability and degree of malignancy. MRP-1/CD9 belongs to the
transmembrane 4 superfamily (TM4SF), which is characterised by
four transmembrane domains delimiting two extracellular regions
of unequal size, as well as a particular fold in the large extracellular
loop (Wright and Tomlinson, 1994).
KAI1/CD82 is also a member of TM4SF. KAI1/CD82 expression
suppressed experimental metastasis of rat prostate tumour cells
(Dong et al, 1995), and decreased motility and invasion of colon
carcinoma cells (Takaoka et al, 1998). KAI1/CD82 is considered to
be a metastasis-suppressor gene of prostate cancer and low KAI1/
CD82 expression has been reported to be involved in the malignant
progression of prostate cancer (Dong et al, 1996). We also showed
that decreased KAI1/CD82 gene expression was an indicator of
poor prognosis in lung cancer (Adachi et al, 1996), breast cancer
(Huang et al, 1998) and pancreatic cancer (Sho et al, 1998). These
data show that KAI1/CD82 is an important tumour suppressor
gene in cancer metastasis and progression.
On the other hand, CD151 is also a transmembrane molecule
that has been characterised as a member of the evolutionally
conserved TM4SF, and it is known as SFA-1 and PETA-3 (Fitter
et al, 1995; Hasegawa et al, 1996). CD151 cDNA shows an open
reading frame of 253 amino acids that encodes a protein of
molecular mass 28kDa. In addition, human CD151 gene locates on
chromosome 11p15.1. CD151 in involved in cell adhesion, cell
motility, metastasis, and stability and formation of hemidesmo-
somes (Yauch et al, 1998).
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phenotype. In addition, for the most part, they work negatively.
Recently, it was reported to be the first member of the TM4SF to
show signs of being a positive effecter of metastasis (Testa et al,
1999). Moreover, CD151 enhances cell motility and cancer
metastasis (Kohno et al, 2002) and CD151 overexpression leads
to a poor prognosis of the patients with non-small cell lung cancer
(Tokuhara et al, 2001). Therefore, CD151 is a metastasis-associated
antigen that appears to contribute to the metastatic phenotype
positively. These findings set CD151 apart from MRP-1/CD9 and
KAI1/CD82 that appear to act as metastasis-suppressor genes. It
may contribute to the collapse of tetraspanin/tetraspanin com-
plexes. In addition, no consistent findings have been reported as a
prognostic indicator for CD151 gene in colon cancer. As part of
our evaluation of members of the TM4SF as possible prognostic
predictors, we performed a retrospective study on the expression
of the MRP-1/CD9 gene, the recently identified KAI1/CD82 gene
and the CD151 gene in human colon cancer.
MATERIALS AND METHODS
Clinical characteristics of the patients
We studied 146 patients with up to stage III colon cancer who had
undergone surgery at the Department of Surgery of the Kitano
Hospital between October 1994 and May 2001. All patients
underwent curative surgery. The postsurgical staging of each
tumour was classified according to the tumour–node–metastasis
(TNM) staging system (Sobin and Wittekind, 1997). The clinical
characteristics of the patients are presented in Table 1. In all, 84 of
patients were men and 62 were women. The median age of the
patients was 62.8 years, with a range of 35–80 years. The patients
could be broken down into 25 with pathological stage I, 46 with
stage II and 75 with stage III disease. The mean follow-up period
for all patients was 44.3 months, with a range of 6.3–85.9 months.
Tumour specimens
One-half of each fresh tumour tissue specimen was immediately
embedded in optimum cutting temperature compound (Miles,
Kankakee, IL, USA), and frozen in liquid nitrogen immediately
after surgical resection and maintained at  801C until use. Frozen
sections were cut on a cryostat to a thickness of 6mm and were
stained with haematoxylin and eosin and used for immunohisto-
chemical staining. After the connective tissues were trimmed off,
the other-half of the tumour specimen that was then made up of
more than 80% cancer cells was used for the reverse transcriptase–
polymerase chain reaction (RT–PCR) analysis.
Immunohistochemical assays
The assays were carried out as described previously (Hashida et al,
2002a). Endogenous peroxidases were blocked by incubating with
0.3% H2O2 in absolute methanol for 30min. The sections were then
incubated with 5% bovine serum albumin for 2h at room
temperature. Subsequently, replicate sections were incubated for
2h with the anti-MRP-1/CD9 MAb M31-15, the anti-KAI1/CD82
MAb C33 and the anti-CD151 MAb SFA1.2B4, respectively. After
washing three times in phosphate-buffered saline (PBS), they were
then incubated for 1h with biotinylated horse anti-mouse IgG
Table 1 Relation of MRP-1/CD9, KAI1/CD82 and CD151 expression and various prognostic factors in 146 patients with colon cancer
MRP-1/CD9 KAII/CD82 CD151
Clinicopathological
characteristics
Number of
patients Positive Negative P-value Positive Negative P-value Positive Negative P-value
Age (years)
p60 74 35 39 NS 33 41 NS 35 39 NS
X60 72 29 43 30 42 46 26
Sex
Female 62 29 33 NS 29 33 NS 32 30 NS
Male 84 35 49 34 50 49 35
Tumour status
T1 17 9 8 NS 11 6 NS 9 8 0.025
T2 20 8 12 7 13 12 8
T3 83 38 45 38 45 39 44
T4 26 9 17 7 19 21 5
Nodal status
N0 71 39 32 0.007 43 28 o0.001 37 34 NS
N1 33 14 19 11 22 15 18
N2 42 11 31 9 33 29 13
Pathological stage
I 25 13 12 0.030 15 10 o0.001 15 10 NS
II 46 26 20 28 18 22 24
III 75 25 50 20 55 44 31
Differentiation
Well 32 16 16 NS 18 14 NS 14 18 NS
Moderately 101 42 59 40 61 57 44
Poorly 13 6 7 5 8 10 3
Total 146 64 82 63 83 81 65
NS¼not significant.
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the antibody binding was completed using 3,30-diaminobenzidine
tetrahydrochloride, and the sections were lightly counterstained
with Mayer’s haematoxylin. Sections incubated with mouse
myeloma SP2 supernatant and mouse IgG were used as negative
reaction control. Specimens of fibroadenoma of the breast were
used as a positive control.
The samples were classified by two pathologists who had no
knowledge of patients’ clinical status. All sections were scored in
semiquantitative fashion according to the method described
previously (Huang et al, 1998). Briefly, we determined the score
by estimating the percentage of cells that stained for MRP-1/CD9,
KAI1/CD82 and CD151, and multiplying by the assessment
of the intensity of the stain on a 0, 1þ,2 þ or 3þ scale (0, no
staining; 1þ, weak staining; 2þ, distinct staining; 3þ,
very strong staining). The theoretical limits of the scores
ranged from 0 (0% of cells staining) to 300 (100% of the cells
staining at 3þ intensity). Significant differences were found
with respect to the survival rate when a score of 120 was used as a
cut off value. Specimens with a score of X120 were classified as
positive, and when score was o120, specimens were classified as
negative.
Semiquantitative RT–PCR analysis
Reverse transcriptase–polymerase chain reaction was performed
as described previously in order to confirm the results of MRP-1/
CD9, KAI1/CD82 and CD151 expression in immunohistochemical
studies (Adachi et al, 1996). Total cellular RNA was extracted from
the frozen tumour tissues by the acid guanidium thiocyanate
procedure (Chomczynski and Sacchi, 1987). First-strand comple-
mentary DNA (cDNA) synthesis was performed with 5mg of total
RNA using a cDNA synthesis kit (Pharmacia, Piscataway, NJ, USA)
following the manufacturer’s protocol. We used 1ml aliquot of the
reaction mixture for PCR amplification. We titrated the amount of
starting cDNA and determined the number of amplification cycles
to obtain reproducible quantitative performance of the RT–PCR
assay for MRP-1/CD9, KAI1/CD82 and CD151. The generated
cDNA was amplified using primers for MRP-1/CD9 (50-TGCATC-
TGTATCCAGCGCCA-30 and 50-CTCAGGGATGTAAGCTGACT-30),
KAI1/CD82 (50-AGTCCTCCCTGCTGCTGTGTG-30 and 50-TCAGT-
CAGGGTGGGCAAGAGG-30) and CD151 (50-ATGGGTGAGTT-
CAACGAGAAG-30 and 50-TCAGTAGTGCTCCAGCTTC-AG-30).
The internal control was b-actin (50-GATATCGCCGCG-
CTCGTCGTCGAC-30 and 50-CAGGAAGGAAGGCTGGAAGAG-
TGC-30). All of the subsequent assays were then performed under
conditions that produced amplifications of MRP-1/CD9, KAI1/
CD82, CD151 and b-actin within a linear range. A total of 24 cycles
of PCR amplification was performed for MRP-1/CD9, KAI1/CD82
and b-actin, and 20 cycles for CD151 as follows: denaturation at
94
oC for 40s, annealing at 60
oC for 40s and extension at 721C for
90s. The same PCR conditions were used to amplify the b-actin
DNA. Tubes containing all of the ingredients except templates
were included in all runs and served as negative controls.
Preparations of the human endothelial cell line ECV304, which is
positive for MRP-1/CD9, KAI1/CD82 and CD151, were used as a
positive control. The amplified PCR products were electrophoresed
on a 1% agarose gel containing ethidium bromide, and the bands
were visualised under ultraviolet light followed by densitometric
analysis. In addition, the resulting PCR products were analysed by
sequencing to confirm their identity as described previously
(Onuma et al, 1999; Rae et al, 2000). PCR products were
successfully sequenced. Sequence comparisons coincided with
the known MRP-1/CD9, KAI1/CD82 and CD151 genes.
The densitometric values obtained for MRP-1/CD9, KAI1/CD82
and CD151 bands in a given tumour tissue sample were divided by
the corresponding value of b-actin for normalisation, and the ratio
was referred to as the gene expression ratio for each gene. The
expression ratio of the tumour was then divided by that of the
human endothelial cell line ECV304 to obtain the gene conserva-
tion rate for MRP-1/CD9, KAI1/CD82 and CD151. We arbitrarily set
several cutoff values to select the best value. When 0.8 was used as
a cutoff value, significant differences were found in survival. We
therefore selected 0.8 as the most appropriate cutoff value. When
the conservation rate value of a given specimen was Z0.8, it was
considered to indicate positive gene expression. If the value was
o0.8, it was considered to indicate negative gene expression
(Figure 1).
Statistical analysis
The statistical significance of the difference between the
incidence of MRP-1/CD9, KAI1/CD82 and CD151 expression and
clinical and pathologic parameters was assessed by the w
2 test
or Mann–Whitney U-test. Overall cancer-specific survival
was defined as from the date of surgery to the date of death
due to cancer. The Kaplan–Meier method was used to estimate
the probability of overall survival as a function of time
(Kaplan and Meier, 1958) and was compared using the
log-rank test (Mantel, 1966). Multivariate analysis was perfor-
med using the Cox regression model (Cox, 1972) to study
the effects of different variables on survival, and eight factors
(MRP-1/CD9 status, KAI1/CD82 status, CD151 status, sex, age,
tumour status, nodal status and histological differentiation) were
studied. Scores were assigned to each variable for regression
analysis. All P-values were based on two-tailed statistical analysis,
and a P-value of o0.05 was considered to indicate statistical
significance.
Figure 1 Agarose gel electrophoresis of RT–PCR-amplified MRP-1/CD9,
KAII/CD82, CD151 and b-actin. Lane 1, size marker; lane 2, human
endothelial cell line ECV304(positive control); lane 3, colon cancer with
MRP-1/CD9-, KAII/CD82- and CD151-positive expression; lane 4, colon
cancer with MPR-1/CD9- and KAII/CD82-positive but CD151-negative
expression; lane 5, colon cancer with MRP-1/CD9- and CD151-positive but
KAII/CD82-negative expression; lane 6, colon cancer with MRP-1/CD9-
positive but KAII/CD82- and CDI5I-negative expression; lane 7, colon cancer
with KAII/CD82- and CD151-positive but MRP-1/CD9-negative expression;
lane 8, colon cancer with KAII/CD82-positive but MRP-1/CD9- and CD151-
negative expression; lane 9, colon cancer with CD151-positive but MRP-1/
CD9- and KAII/CD82-negative expression; lane 10, colon cancer with MRP-
1/CD9-, KAII/CD82- and CD151-negative expression.
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MRP-1/CD9, KAI1/CD82 and CD151 gene expression in
colon cancer tissues analysed by RT–PCR
Of the 146 colon cancers studied, 82 carcinomas (43.8%) were
evaluated as MRP-1/CD9-positive and 64 carcinomas (56.2%) as
MRP-1/CD9-negative expression. In all, 63 carcinomas (43.2%)
were evaluated as KAI1/CD82-positive and 83 carcinomas (56.8%)
as KAI1/CD82-negative expression. A total of 81 carcinomas
(55.5%) were evaluated as CD151-positive and 65 carcinomas
(44.5%) as CD151-negative expression (Table 1 and Figure 1).
Immunohistochemical study of MRP-1/CD9, KAI1/CD82
and CD151 in colon cancer tissues
Of the 146 colon cancers studied using the immunohistochemical
method, 69 (49.1%) were classified as MRP-1/CD9 positive
(Figure 2A), and the immunostaining was intense and uniform
on the cell surface membrane in these specimens. There were 77
specimens (50.9%) with negative MRP-1/CD9 expression
(Figure 2B). The immunohistochemical results agreed well with
those from the RT–PCR assays, and 92.5% of the specimens
coincided exactly.
Figure 2 Immunohistochemical staining of human colon cancer tissues using the avidin–biotin–peroxidase complex procedure (original
magnification, 150). (A) MRP-1/CD9-positive staining of colon cancer; (B) MRP-1/CD9 negative staining of colon cancer; (C) KAII/CD82-positive staining
of colon cancer; (D) KAI1/CD82-negative staining of colon cancer; (E) CD151-positive staining of colon cancer; (F) CD151-negative staining of colon cancer.
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with positive KAI1/CD82 expression and 79 specimens (54.1%)
with negative KAI1/CD82 expression (Figure 2C, D). These results
agreed well with those from the RT–PCR assays, and 93.4% of the
specimens coincided exactly.
Furthermore, there were 78 specimens (53.4%) with positive
CD151 expression and 68 specimens (46.6%) with negative CD151
expression (Figure 2E, F). These results agreed with those from the
RT–PCR assays, and 88.9% of the specimens coincided exactly.
Relation between MRP-1/CD9, KAI1/CD82 and CD151
expression and various prognostic factors
The relation between MRP-1/CD9 gene expression and various
prognostic factors is shown in Table 1. The relation was found
between MRP-1/CD9 gene expression and nodal status (P¼0.007)
and pathological stage (P¼0.030). In all, 32 (45.1%) patients with
N0 stage had negative gene expression compared with 57.6% of N1
stage patients and 75.6% of N2 stage patients. In addition, the
percentage of patients whose tumours had MRP-1/CD9-negative
gene expression increased from 48.0% of those with stage I to
66.7% of those with stage III.
In contrast, KAI1/CD82 gene expression was associated with
lymph node status (Po0.001) as well as pathological stage
(Po0.001). A total of 28 (39.4%) patients with N0 stage had
negative gene expression compared with 66.7% of N1 stage
patients and 78.6% of N2 stage patients. With respect to
pathological stage, the percentage of patients whose tumours had
KAI1/CD82-negative gene expression increased from 40.0% of
those with stage I to 73.3% of those with stage III.
The relation between CD151 gene expression and various
prognostic factors is shown in Table 1. There was a statistically
significant relation between gene expression and tumour status
(P¼0.025). Eight patients (47.1%) with T1 stage had negative gene
expression compared with 19.2% of T4 stage patients.
Relation between MRP-1/CD9 expression and 3-year,
disease-free and overall survival of colon cancer patients
Among all 146 patients, the 3-year survival rate of patients with
MRP-1/CD9-positive tumours was significantly higher than that of
patients with MRP-1/CD9-negative tumours (98.1 vs 76.0%,
Po0.001; Table 2). In addition, the disease-free survival rate of
patients with MRP-1/CD9-positive tumours was significantly
higher than that of patients with MRP-1/CD9-negative tumours
(74.8 vs 43.5%, P¼0.004; Table 2). Similarly, the overall survival
rate for patients with positive tumours was significantly better than
that of individuals whose tumours had negative MRP-1/CD9
expression (89.8 vs 50.8%, Po0.001; Table 2 and Figure 3). In
particular, MRP-1/CD9 was an effective indicator for patients with
advanced disease (N2 status and stage III).
Relation between KAI1/CD82 expression and 3-year,
disease-free and overall survival of colon cancer patients
Among the 146 patients, the 3-year survival rate of patients with
KAI1/CD82-positive tumours was significantly higher than that of
patients with KAI1/CD82-negative tumours (98.2 vs 75.7%,
Po0.001; Table 3). In addition, the disease-free survival rate of
patients with KAI1/CD82-positive tumours was significantly higher
than that of patients with KAI1/CD82-negative tumours (77.1 vs
42.3%, P¼0.004; Table 3). Moreover, the overall survival rate for
patients with positive tumours was significantly better than that of
Table 2 Survival rate of 146 patients with colon cancer according to clinicopathological characteristics and MRP-1/CD9
3-year survival rate (%) Disease-free survival rate (%) Overall survival rate (%)
Clinicopathological characteristics Positive Negative P-value Positive Negative P-value Positive Negative P-value
Age (years)
p60 96.4 87.2 0.185 78.1 41.3 0.032 88.0 56.3 0.056
X60 100.0 65.8 0.004 67.5 25.3 0.051 92.3 47.5 0.002
Sex
Female 100.0 83.7 0.049 77.7 44.1 0.057 89.5 63.9 0.044
Male 96.6 71.8 0.009 71.6 40.8 0.057 90.9 41.3 0.002
Tumour status
T1 100.0 100.0 40.999 100.0 50.0 0.400 100.0 50.0 0.400
T2 100.0 66.7 0.192 77.2 33.3 0.118 80.0 33.3 0.260
T3 100.0 94.4 0.499 75.0 23.3 0.174 95.2 72.4 0.042
T4 83.3 29.4 0.041 50.1 12.3 0.170 55.6 15.7 0.047
Nodal status
N0 100.0 100.0 40.999 86.6 32.5 0.160 95.2 73.8 0.628
N1 100.0 100.0 40.999 87.5 64.8 0.328 90.0 77.1 0.458
N2 88.9 35.3 0.012 68.6 10.2 0.045 74.1 12.1 0.003
Pathological stage
I 100.0 100.0 40.999 72.2 23.7 0.789 100.0 75.0 0.400
II 100.0 100.0 40.999 85.2 54.4 0.236 91.7 75.0 0.690
III 95.2 60.7 0.006 79.0 34.7 0.013 82.9 37.2 0.002
Differentiation
Well 100.0 86.7 40.999 83.3 28.4 0.469 100.0 34.2 40.999
Moderately 97.1 78.7 0.019 80.1 27.8 0.074 85.0 64.5 0.049
Poorly 100.0 20.0 0.015 100.0 0.0 0.008 100.0 0.0 0.008
Total 98.1 76.0 o0.001 74.8 43.5 0.004 89.8 50.8 o0.001
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(84.8 vs 54.9%, P¼0.002; Table 3 and Figure 4).
Relation between CD151 expression and 3-year, disease-
free and overall survival of colon cancer patients
Among all 146 patients, the 3-year survival rate of patients with
CD151-positive tumours was significantly lower than that of
patients with CD151-negative tumours (78.5 vs 94.3%, P¼0.012;
Table 4). In addition, the disease-free survival rate of patients with
CD151-positive tumours was significantly lower than that of
patients with CD151-negative tumours (53.6 vs 61.2%, P¼0.048;
Table 4). Moreover, the overall survival rate for patients with
negative tumours was significantly better than that of individuals
whose tumours had positive CD151 expression (61.2 vs 74.9%,
P¼0.022; Table 4 and Figure 5).
Prognostic value of MRP-1/CD9, KAI1/CD82 and
CD151 expression
The Cox regression model was used to evaluate disease-free and
overall survival as shown in Table 5. Two variables, nodal status
(Po0.001) and MRP-1/CD9 status (P¼0.015), were significant
factors in predicting the disease-free survival of colon cancer
patients. Moreover, three variables, nodal status (Po0.001),
tumour status (P¼0.029) and MRP-1/CD9 status (P¼0.015), were
significant factors in predicting the overall survival of colon cancer
patients.
DISCUSSION
Colon cancer has become one of the most common causes of
cancer death in Japan (Health and Welfare Statistics Association,
1998). Endoscopic treatments for early stage of colon cancer have
been improved, but no established treatment is available for
patients in the advanced stage. Up until now, the prognosis of
patients with colon cancer has depended on the clinicopathological
staging. However, recently, molecular assessment has been
incorporated into treatment of patients with colon cancer (Boland
et al, 2000). It is well known that the accumulation of genetic
alterations facilitates the progression of tumours. The famous
model of colorectal tumorigenesis shows that three tumour
Figure 3 Overall survival of 146 colon cancer patients according to their
tumour MRP-1/CD9 gene status.
Table 3 Survival rate of 146 patients with colon cancer according to clinicopathological characteristics and KAI1/CD82
3-year survival rate (%) Disease-free survival rate (%) Overall survival rate (%)
Clinicopathological characteristics Positive Negative P-value Positive Negative P-value Positive Negative P-value
Age (years)
p60 96.6 87.1 0.176 82.1 47.2 0.080 86.8 62.8 0.118
X60 100.0 63.7 0.001 50.8 36.7 0.020 78.7 51.5 0.006
Sex
Female 100.0 84.8 0.112 100.0 33.3 0.021 100.0 60.6 0.013
Male 96.7 69.8 0.006 57.7 42.3 0.232 73.9 44.5 0.051
Tumour status
T1 100.0 100.0 40.999 100.0 0.0 0.250 100.0 0.0 0.200
T2 100.0 70.5 0.209 100.0 0.0 0.036 100.0 0.0 0.048
T3 100.0 94.2 0.495 75.0 66.3 0.413 81.2 83.7 0.863
T4 80.0 33.8 0.115 35.6 20.3 0.480 40.0 22.1 0.190
Nodal status
N0 100.0 100.0 40.999 75.0 22.7 40.001 100.0 42.6 0.048
N1 100.0 100.0 40.999 71.4 65.9 0.823 75.0 87.5 0.539
N2 87.5 38.1 0.028 27.8 22.2 0.610 43.8 24.2 0.082
Pathological stage
I 100.0 100.0 40.999 66.7 0.0 o0.001 100.0 66.7 0.300
II 100.0 100.0 40.999 100.0 40.9 0.236 100.0 45.8 0.400
III 94.1 64.2 0.025 53.1 45.6 0.556 61.0 49.1 0.173
Differentiation
Well 100.0 84.6 0.192 75.0 18.8 0.035 83.3 30.8 0.138
Moderately 97.1 78.7 0.020 55.5 46.5 0.126 87.4 62.4 0.021
Poorly 100.0 33.3 0.061 75.0 25.6 0.090 75.0 33.3 0.103
Total 98.2 75.7 o0.001 77.1 42.3 o0.001 84.8 54.9 0.002
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K-ras play key roles in the progression of colon cancer (Feason and
Vogelstein, 1990). In addition, many other prognostic factors have
been examined for colon cancer. However, little is understood
about the genetic alternations and cellular mechanisms that are
responsible for the final steps in tumour metastasis (Haier et al,
2000). An enhanced understanding of the molecular genetic events
that occur during progression in colon cancer could lead to new
therapeutic modalities and improvement in survival rates.
In the present study, we investigated the gene expressions of the
three TM4SF members, MRP-1/CD9, KAI1/CD82 and CD151. This
TM4SF is made up of approximately 23 members. These proteins
are variously expressed in leucocytes and a variety of non-
haematopoietic tissues. MRP-1/CD9 is a glycoprotein widely
expressed not only in haematopoietic tissues, platelets, early B
cells, activated T cells and granulocytes, but also in nonhaemato-
poietic tissues (Wright and Tomlinson, 1994). CD9 null female
displays a severe reduction in fertility and CD9 appears to be
essential for sperm–egg fusion, a process involving the
CD9-associated integrin a6b1 (Le Naour et al, 2000). TM4SF
proteins act as links between extracellular integrins and intracel-
lular signalling molecules, such as phosphatidylinositol 4-kinase
(Yauch et al, 1998) and TM4SF proteins appear to regulate cell
motility through this link (Hemler, 1996; Berditchevski and
Odintsova, 1999). Several studies suggest that TM4SF plays an
important role in the regulation of cell development, activation,
proliferation and adhesion (Wright and Tomlinson, 1994; Hemler
et al, 1996; Hashida et al, 2002b). Interestingly, several TM4SF
member proteins have been associated with the metastatic
phenotype, but these associations have been, for the most part,
negative. Previously, we showed that reductions of MRP-1/CD9 and
KAI1/CD82 were predictive factors for a poor prognosis in patients
with various kinds of cancers. As part of our evaluation of
members of TM4SF as possible prognostic predictors, we further
extended our study to the expression of CD151 and performed a
retrospective study on the expression of CD151, MRP-1/CD9 and
KAI1/CD82 in colon cancer. CD151 was reported to be a
metastasis-associated antigen that appeared to contribute posi-
tively to the metastatic phenotype in contrast to the MRP-1/CD9,
KAI1/CD82 and ME491/CD63 (Testa et al, 1999). In addition, it
was reported that CD151 may not affect tumour cell proliferation
Figure 4 Overall survival of 146 colon cancer patients according to their
tumour KAII/CD82 gene status.
Table 4 Survival rate of 146 patients with colon cancer according to clinicopathological characteristics and CD151
3-year survival rate (%) Disease-free survival rate (%) Overall survival rate (%)
Clinicopathological characteristics Positive Negative P-value Positive Negative P-value Positive Negative P-value
Age (years)
p60 87.5 94.3 0.298 57.8 66.1 0.281 67.9 75.4 0.213
X60 70.7 94.4 0.030 49.3 62.4 0.118 58.4 72.6 0.087
Sex
Female 92.3 91.5 0.900 60.7 60.0 0.466 75.2 79.3 0.887
Male 69.3 96.7 0.005 49.4 61.2 0.065 51.6 72.6 0.010
Tumour status
T1 100.0 100.0 40.999 50.0 100.0 0.400 50.0 100.0 0.400
T2 80.0 83.3 0.853 62.3 40.0 0.653 66.7 40.0 0.805
T3 96.4 97.4 0.914 60.2 56.6 0.159 83.2 88.3 0.887
T4 33.8 80.0 0.115 16.9 55.3 0.451 16.9 53.3 0.159
Nodal status
N0 100.0 100.0 40.999 84.8 78.5 0.447 88.1 80.0 0.418
N1 100.0 100.0 40.999 56.1 62.3 0.797 70.0 92.9 0.150
N2 42.3 72.5 0.111 30.4 0.0 0.371 32.9 0.0 0.726
Pathological stage
I 100.0 100.0 40.999 85.7 100.0 40.999 85.7 100.0 40.999
II 100.0 100.0 40.999 80.1 51.1 0.071 90.0 75.0 0.589
III 60.4 88.9 0.010 40.7 40.7 0.147 42.6 66.4 0.033
Differentiation
Well 85.7 100.0 0.483 40.9 42.9 0.266 42.9 45.0 0.158
Moderately 77.0 97.5 0.008 50.3 64.3 0.033 58.9 89.0 0.006
Poorly 75.0 33.3 0.188 64.3 0.0 0.123 75.0 0.0 0.034
Total 78.5 94.3 0.012 53.6 61.2 0.048 61.2 74.9 0.022
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secondary metastatic lesions. The ability of CD151 to mediate
tumour cell migration may provide a possible mechanism for the
role of this protein in effecting metastatic dissemination. More-
over, it was reported that the CD151molecule enhances cell
motility, invasion and metastasis of cancer cells and that focal
adhesion kinase is needed for these events through CD151 (Kohno
et al, 2002). We have hypothesised that those patients with a
CD151-positive tumour are in a more advanced stage of the disease
and have a much poorer prognosis. In this study, the CD151
mRNA levels and protein expression were associated with tumour
status. Moreover, our present study showed that there was a
significant difference between the overall survival rate for colon
cancer patients with low CD151 expression and that of patients
with CD151-positive tumours. These findings suggest that CD151
may play an important role in the progression in colon cancer
cells, and that its expression may have an effect on the
characteristics of colon cancers. Further basic studies using an
experimental metastasis model will be necessary.
On the other hand, KAI1/CD82 expression was demonstrated to
be consistently downregulated during the progression of human
colon cancer, as well as breast cancer (Huang et al, 1998),
pancreatic cancer (Sho et al, 1998) and nonsmall cell lung cancer
(Adachi et al, 1996). Furthermore, we have shown that the survival
rate for colon cancer patients with negative KAI1/CD82 expression
was strikingly lower than that of patients with KAI1/CD82-positive
tumours. Similarly, the survival rate of patients with MRP-1/CD9-
negative tumours was significantly lower than that of patients with
MRP-1/CD9-positive tumours. The malignancy-suppressing effect
of CD82 or CD9 may be based partially on cell motility inhibition
Figure 5 Overall survival of 146 colon cancer patients according to their
tumour CD151 gene status.
Table 5 Multivariate regression analysis in predicting the disease-free and overall survival of 146 patients
with colon cancer
Disease-free survival Overall survival
Variables
Assigned
score
Hazard ratio
(95% CI) P-value
Hazard
ratio (95% CI) P-value
MRP-11CD9
Positive 0 3.147(1.240–7.940) 0.015 5.511(1.584–19.158) 0.007
Negative 1
KAI1/CD82
Positive 0 0.949 (0.388–2.321) 0.909 1.107 (0.364–3.369) 0.858
Negative 1
CD151
Negative 0 0.529 (0.247–1.123) 0.097 0.603 (0.028–1.597) 0.309
Positive 1
Age (years)
p60 0 1.491 (0.748–2.974) 0.257 1.258(0.569–2.782) 0.571
X60 1
Sex
Female 0 1.374 (0.699–2.702) 0.357 1.838 (0.786–4.300) 0.160
Male 1
Tumour status
T1 1 1.561 (0.942–2.585) 0.084 2.066 (1.101–3.874) 0.024
T2 2
T3 3
T4 4
Nodal status
N0 0 2.812 (1.736–4.556) o0.001 3.797 (1.981–7.277) o0.001
N1 1
N2 2
Differentiation
Well 0 0.811 (0.422–1.559) 0.530 0.815(0.384–1.728) 0.593
Moderately 1
Poorly 2
Abbreviation: CI¼confidence interval.
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and N-glycosylation (Ono et al, 1999). Although the precise
mechanism remains unknown, the levels of the MRP-1/CD9 or
KAI1/CD82 gene may be diminishing due to promoter abnormality
or aberrant glycosylation may have occurred in the first hydro-
philic region and normal MRP-1/CD9 or KAI1/CD82 function
could be lost. Hence, GM3 and other lipids may contribute to the
formation of tetraspanin/tetraspanin complexes. Our present study
suggests that cancer progression may lead to collapse of tetras-
panin/tetraspanin complexes as well as the collapse of tetraspanin/
integrin complexes. In addition, a link between a tetraspanin and
Rho GTPase cascade may explain why members of TM4SF are
involved in cell activation, adhesion, growth and metastasis
(Delaguillaumie et al, 2002). Although the precise biological
functions of these proteins remain unknown, the downregulation
of KAI1/CD82 and MRP-1/CD9 genes during the progression of
human cancer is highly associated with a poor prognosis.
The classification of colon cancers according to MRP-1/CD9,
KAI1/CD82 and CD151 expression might be useful in identifying
patients for whom intensive adjuvant therapy is warranted. It is
conceivable that testing tumours for TM4SF expression, in
combination with other molecular and biochemical assays, may
improve the prognostic evaluation of colon cancer patients, and
enhance the clinician’s ability to prospectively identify patients
who will have early disease recurrence and who require adjuvant
chemotherapy.
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